SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and ...
Volta Labs and Ginkgo Bioworks (DNA) announced the integration of the Callisto Sample Prep System at Ginkgo Bioworks as part of the routine ...
Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...
Market OverviewThe global Molecular Diagnostics Market is valued at USD 14.9 Billion in 2022 and is projected to reach a value of USD 35.8 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 11 ...
Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...
Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, expectations were $0.92. Operator: Good day, ladies and gentlemen, and ...
Illumina Inc (NASDAQ:ILMN). reported stronger-than-expected earnings for the fourth quarter of 2024, with both earnings per share (EPS) and revenue surpassing analysts' forecasts. Despite the positive ...
Illumina's performance in Q4 2024 showed modest growth, with a 1% year-over-year increase in revenue. The company continues to lead in the genomics sector, driven by advancements in sequencing ...
Genomics company Illumina (NASDAQ:ILMN) will be reporting results tomorrow after the bell. Here’s what investors should know. Illumina met analysts’ revenue expectations last quarter ...
(Reuters) -Shares of genetic testing company Illumina and Calvin Klein-owner PVH Corp fell on Tuesday after China placed the two companies on its "unreliable entity" list, putting them at risk of ...
Shares of genomics company Illumina (NASDAQ:ILMN) fell 6.3% in the afternoon session after China put the company on its "unreliable entity" list, opening the door to possible sanctions.